Loading organizations...
§ Private Profile · Zwijnaarde, Oost-Vlaanderen, Belgium
Biotechnology single-domain antibody therapies for viral infections, focused on respiratory viruses and immunocompromised patients.
ExeVir Bio is a Ghent, Belgium-based biotechnology company that develops single-domain antibody therapies derived from llamas to target viral respiratory infections. The clinical-stage firm utilizes a modular platform to engineer multi-specific antibodies with extended half-lives, focusing on providing broad protection for immunocompromised and elderly patients against diseases like COVID-19 and influenza. The organization recently advanced its lead COVID-19 antibody candidate, XVR013m, through Phase 1a and 1b clinical trials. To support its research and clinical pipeline, the enterprise has secured €42 million in Series A venture capital financing alongside €18 million in non-dilutive European grant funding. ExeVir Bio is backed by a syndicate of prominent institutional investors that includes Fund+, UCB Ventures, V-Bio Ventures, and SRIW. The company was founded in 2020 by professors Nico Callewaert and Xavier Saelens.
ExeVir Bio has raised $105.5M across 4 funding rounds.
ExeVir Bio has raised $105.5M in total across 4 funding rounds.
ExeVir Bio has raised $105.5M in total across 4 funding rounds.
ExeVir Bio's investors include VLAIO, Kris Peeters, Philippe Monteyne, Belgian family offices, Noshaq, Sambrinvest, Stef HEYLEN, MD, Caroline THIELEN, Erica Whittaker, Katja Rosenkranz, Jerome Van Biervliet, Joël Henneghien.
ExeVir Bio has raised $105.5M across 4 funding rounds. Most recently, it raised $1.8M Grant in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 28, 2023 | $1.8M Grant | Vlaio | — | Announced |
| Jan 9, 2023 | $26.7M Debt Financing | Kris Peeters | — | Announced |
| May 24, 2021 | $50M Series A | Philippe Monteyne | Belgian Family Offices, Noshaq, Sambrinvest, Stef Heylen, MD, Caroline Thielen, Erica Whittaker, Katja Rosenkranz, Jerome VAN Biervliet, Joël Henneghien | Announced |
| Jul 28, 2020 | $27M Venture Round | Philippe Monteyne | Sfpi Fpim, Erica Whittaker, Katja Rosenkranz, Jerome VAN Biervliet | Announced |